liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Next-Generation Sequencing Reveals That HLA-DRB3, -DRB4, and -DRB5 May Be Associated With Islet Autoantibodies and Risk for Childhood Type 1 Diabetes
Fred Hutchinson Cancer Research Centre, WA 98104 USA.
Lund University, Sweden.
Fred Hutchinson Cancer Research Centre, WA 98104 USA.
Lund University, Sweden.
Show others and affiliations
2016 (English)In: Diabetes, ISSN 0012-1797, E-ISSN 1939-327X, Vol. 65, no 3, 710-718 p.Article in journal (Refereed) PublishedText
Abstract [en]

The possible contribution of HLA-DRB3, -DRB4, and -DRB5 alleles to type 1 diabetes risk and to insulin autoantibody (IAA), GAD65 (GAD autoantibody [GADA]), IA-2 antigen (IA-2A), or ZnT8 against either of the three amino acid variants R, W, or Q at position 325 (ZnT8RA, ZnT8WA, and ZnT8QA, respectively) at clinical diagnosis is unclear. Next-generation sequencing (NGS) was used to determine all DRB alleles in consecutively diagnosed patients ages 1-18 years with islet autoantibody-positive type 1 diabetes (n = 970) and control subjects (n = 448). DRB3, DRB4, or DRB5 alleles were tested for an association with the risk of DRB1 for autoantibodies, type 1 diabetes, or both. The association between type 1 diabetes and DRB1*03:01:01 was affected by DRB3*01:01:02 and DRB3*02:02:01. These DRB3 alleles were associated positively with GADA but negatively with ZnT8WA, IA-2A, and IAA. The negative association between type 1 diabetes and DRB1*13:01:01 was affected by DRB3*01:01:02 to increase the risk and by DRB3*02:02:01 to maintain a negative association. DRB4*01:03:01 was strongly associated with type 1 diabetes (P = 10(-36)), yet its association was extensively affected by DRB1 alleles from protective (DRB1*04:03:01) to high (DRB1*04:01:01) risk, but its association with DRB1*04:05:01 decreased the risk. HLA-DRB3, -DRB4, and -DRB5 affect type 1 diabetes risk and islet autoantibodies. HLA typing with NGS should prove useful to select participants for prevention or intervention trials.

Place, publisher, year, edition, pages
AMER DIABETES ASSOC , 2016. Vol. 65, no 3, 710-718 p.
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:liu:diva-126246DOI: 10.2337/db15-1115ISI: 000370961000024PubMedID: 26740600OAI: oai:DiVA.org:liu-126246DiVA: diva2:913456
Note

Funding Agencies|European Foundation for the Study of Diabetes Clinical Research Grants Programme; Swedish Child Diabetes Foundation; National Institutes of Health [DK-63861, DK-26190]; Swedish Research Council; Linne grant; Skane County Council for Research and Development; Swedish Association of Local Authorities and Regions; Knut and Alice Wallenberg Foundation

Available from: 2016-03-21 Created: 2016-03-21 Last updated: 2016-03-21

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Ludvigsson, JohnnySamuelsson, Ulf
By organisation
Division of Clinical SciencesFaculty of Medicine and Health SciencesDepartment of Paediatrics in Linköping
In the same journal
Diabetes
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 169 hits
ReferencesLink to record
Permanent link

Direct link